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Abstract 
Cardiovascular disease (CVD) is the leading cause of mortality globally, and a major 
contributor to disability. There exist several well-established CVD risk factors, many of 
which are used in clinical practice. Nonetheless, these risk factors do not fully explain 
why certain individuals develop CVD. Several additional risk factors for CVD have been 
proposed which deserve to be examined further in prospective studies. Therefore, the 
overall aim of this thesis was to gain a comprehensive understanding of the 
epidemiology of well-established and promising risk factors for CVD. 
In study I, we estimated the additive and non-additive genetic components contributing 
to variation in established CVD biomarkers. We could show that all of the traits were to 
some extent influenced by genetics, and that many of them were under the influence of 
non-additive genetic effects. 
In study II, we examined how variation in anti-PC levels and Lp-PLA2 activity is 
explained by genetic and environmental effects and how these effects are shared with 
other established CVD biomarkers. Both of these traits were found to be affected by 
genetic and environmental effects, Lp-PLA2 activity was moderately correlated with 
several of the other biomarkers while anti-PC appeared to be regulated independently 
of more established CVD biomarkers. 
In study III, we investigated whether clinical depression and use of antidepressants are 
associated with CVD outcome. Further, we examined if the associations were more 
specific for CHD or ischemic stroke. Depression was found to be a possible risk factor 
for the development of CVD, more specifically stroke. 
In study IV, we investigated if individuals with any record of clinical depression or self-
reported depressive symptoms had an increased risk for incident stroke after adjusting 
for a range of stroke risk factors. The association between depression and stroke could 
not be accounted for by traditional stroke risk factors. 
In conclusion, CVD is a highly complex disorder affected by a multitude of risk factors, 
which in themselves are influenced by both our genetic make-up and environmental 
exposure. Although there exist well-established CVD risk factors useful in CVD risk 
assessment, novel CVD risk factors should be more thoroughly investigated in future 
studies. Such studies might not only add information that would be useful in CVD risk 
stratification, they could also enhance our biological understanding of this complex 
disorder. 
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1 Background 
1.1 CVD and Atherosclerosis 
 
Cardiovascular disease (CVD) is the major contributor to mortality and disability world-
wide, as can been seen in figure 1. There has been a decline in CVD mortality in high-
income countries over the years, but CVD mortality is unfortunately increasing in low- 
and middle-income countries 1.  
 
 
 
 
 
Figure 1. Chart showing the distribution of major causes of mortality worldwide in 2008 
(adapted from the World Health Organization) 
 
CVD include numerous complications which affect the heart and blood vessels, many of 
which have its origin in atherosclerosis.  Atherosclerosis is a condition in which an 
artery wall is damaged due to plaque formation.  The underlying mechanism involves 
the deposition and entrapment of modified LDL, for instance oxidized LDL, in the 
arterial wall which in turn attracts macrophages which internalizes the modified LDL 
upon which lipid peroxides are generated. Consequently cholesterol esters are 
accumulated and foam cells are formed 2-4. Atherosclerotic lesions are characterized by 
a build-up of lipids in the artery walls, followed by inflammatory response. 
CVD 32% 
Other non 
communicable 
diseases 33% 
Communicable 
diseases 27% 
Injuries 9%  
2 
 
Inflammatory and immune cells constitute an important part of an atherosclerotic 
lesion, the remainder being vascular endothelial and smooth-muscle cells 5. When the 
endothelium, the single layer of cells on the arterial wall, is damaged, smooth muscle 
cells proliferate which leads to further narrowing of the arterial lumen. Macrophages 
and foam cells secrete metalloproteinases and tissue factors which degrade the 
vulnerable plaque which eventually leads to plaque rupture and thrombosis 2,6. If the 
plaque rupture prevents blood flow through the coronary arteries it could lead to 
unstable angina or myocardial infarction 5,7. Plaque rupture could also lead to stroke 
when the plaque obstructs a cerebral artery, or if the plaque originates elsewhere but 
detaches and moves to the circulation and occludes smaller vessels producing embolism 
2. 
1.2 CVD biomarkers 
The cardiovascular research field has been very successful in finding biomarkers for 
CVD risk assessment. As an example, the framingham heart study has been a milestone 
in CVD risk stratification, investigating the relationship of total cholesterol (TC), low 
density lipoprotein (LDL), high density lipoprotein (HDL), age, and sex with 10 year risk 
of CHD development 8. Besides LDL and HDL who constitute a major role in the 
development of atherosclerosis, their lipoprotein constituents’ apolipoprotein B (apoB) 
and apolipoprotein A-I (apoA-I) have also shown to add information in CVD risk 
prediction 9.  
A large number of studies have shown hyperglycemia, elevated triglycerides (TG) and 
glycated hemoglobin (HbA1c) to be associated with CVD risk, this association has been 
confirmed independent of diabetes. Elevated levels of TG are recognized as a risk factor 
in guidelines used for CVD risk assessment 10-13. In a study comprising 29 Western 
prospective cohorts, which involved 262 525 study participants and a total of 10 158 
incident CHD cases, triglycerides were reported to be moderately associated with an 
increased risk of CHD development 14. The serum acute phase protein, C-reactive 
protein (CRP), has been proposed to be a risk marker for atherosclerotic progression, 
and has been suggested to be included in risk models for CVD screening 15,16. 
Novel CVD biomarkers 
The constituent papers of this thesis include investigations of the novel biomarkers 
Lipoprotein-associated phospholipase A2 (Lp-PLA2) and IgM antibodies against 
phosphorylcholine (anti-PC). These biomarker’s  influence on CVD development have 
not been as extensively studied as the more established CVD biomarkers mentioned 
earlier, and they are not used in clinical practice. Both these markers are indicators of 
atherosclerotic inflammation, in which Lp-PLA2 has been suggested to exert both pro-
inflammatory and anti-inflammatory effects, while anti-PC predominantly attenuates 
the inflammation in the vessel wall. They both target oxidized LDL and more specifically 
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its phospholipids component.  Both of these biomarkers are described in more detail 
below. 
Oxidative stress 
Oxidative stress is one of the key mechanisms through which atherosclerosis is thought 
to develop. Reactive oxygen species are responsible for the process in which properties 
of phospholipids on lipoproteins are altered and hence become dysfunctional, 
immunogenic, and pro-atherogenic 17. This is highlighted in the oxidation of LDL inside 
the arterial wall which elicits the inflammatory response, triggering the formation of 
atherosclerosis.  
Lp-PLA2 
Lp-PLA2also named plasma Platelet-activating-Factor (PAF)-acetylhydrolase is an 
enzyme secreted by macrophages and circulates primarily bound to LDL, and to much 
lesser extent to HDL. Although Lp-PLA2 is expressed by inflammatory cells throughout 
the body, it is its production by atherosclerotic plaque which may elicit local stimulation 
of the innate immune system 18,19. 
Lp-PLA2 is capable of generating two bioactive pro-inflammatory mediators: free 
oxidized fatty acids and lysophosphatidylcholine 20,21. However, since it also degrades 
PAF and oxidation products of phosphatidylcholine produced upon LDL oxidation 
and/or oxidative stress, it may also be considered as a potentially anti-inflammatory 
enzyme 19,22. Nevertheless, a putative pro-atherogenic role has most widely been 
verified by earlier studies 23,24. According to a comprehensive meta-analysis including 
approximately 80,000 individuals, Lp-PLA2 activity could be found to increase the risk 
of future CHD and stroke even after adjusting for a range CVD risk factors 25. Darapladib 
which is an inhibitor of Lp-PLA2 activity has been found to decrease atherosclerotic 
plaque formation in ApoE-deficient mice as well as in pigs 26,27. Further, a clinical study 
on patients with pre-existing coronary disease showed that treatment with darapladib 
in addition to statin treatment inhibited further growth of the necrotic core in the 
vulnerable plaque compared to placebo treatment 28. 
Lp-PLA2 has also previously been reported to be correlated with several other CVD 
biomarkers; LDL, HDL, apoB, TC, and TG, while weaker correlations were observed 
between Lp-PLA2 and glucose, body mass index(BMI), and systolic blood pressure(SBP) 
25,29,30. 
Anti-PC 
Phosphorylcholine (PC) is a major active component in bacteria, including Streptococcus 
pneumonia, and in apoptotic cells. It is also a component of oxidized LDL. Antibodies 
against PC (anti-PC) are thought to establish a first line defense against infections by 
Streptococcus pneumonia and maybe also other bacteria 31,32. These antibodies belong to 
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the class of natural antibodies 33. Scavenger receptors of macrophages bind oxidation-
specific ligands, including phosphorylcholine-containing oxidized phospholipids, and 
consequently promote uptake of oxidized LDL 35.  
A recent study demonstrated IgM anti-PC to inhibit uptake of oxidized LDL in 
macrophages, possibly reducing foam cell production 34. Immunization with 
pneumococcal vaccine that induces IgM anti-PC antibodies has been demonstrated to be 
atheroprotective in mice and in hypertensive patients 35,36. A previous study reported 
that low levels of anti-PC increase risk of ischemic stroke in men 37. Moreover, it has 
been shown that levels of anti-PC are significantly higher in a population from New 
Guinea with a traditional lifestyle, as compared to Swedish controls, and that CVD is 
rare among individuals from Kitava, New Guinea 38.  
1.3 Stroke 
Stroke occurs due to disturbances of blood perfusion in the brain caused by either 
ischemia or hemorrhage.  Ischemic stroke can be caused by for example embolism, local 
thrombosis, or systemic hypoperfusion (low blood perfusion throughout the body) 39. 
Stroke diagnoses are based on clinical features and on data collected by tests such as 
computed tomography (CT), magnetic resonance imaging (MRI), cardiac imaging, 
duplex imaging of extracranial arteries, arteriography, and laboratory assessments. One 
of the most popular classification systems developed for classifying acute ischemic 
stroke is the Trial of Org 10172 in Acute Stroke Treatment (TOAST). The TOAST 
classification is based on clinical features as well as neurological and laboratory 
assessments. The system includes five categories; 1) large-artery atherosclerosis, 2) 
cardioembolism, 3) small-artery occlusion (lacune), 4) stroke of other determined 
etiology, and 5) stroke of undetermined etiology 40.  
A stroke is diagnosed if a patient has a cerebral dysfunction with symptoms lasting for 
more than 24 hours or that leads to death 41. Transient ischemic attack (TIA) refers to 
ischemic cerebral dysfunction that lasts less than 24 hours and is followed by complete 
neurological recovery 39. 
Risk factors for stroke 
According to the guidelines for stroke prevention developed by the American Heart 
Association there are several non-modifiable and modifiable risk factors for stroke. 
Well-documented non-modifiable risk factors include age, sex, ethnicity, genetic 
predisposition and low birth weight. Well-documented modifiable risk factors comprise 
of high blood pressure, atrial fibrillation, diabetes, cigarette smoking, physical inactivity, 
dyslipidemia, carotid artery disease, other CVD, sickle cell disease, postmenopausal 
hormone therapy, poor nutrition and obesity. Among less well-documented or 
potentially modifiable risk factors they list alcohol consumption, migraine, 
inflammation etc. 42.  
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A recent large-scale international study suggested that hypertension, cigarette smoking, 
diabetes, waist-to-hip ratio, poor nutrition, alcohol consumption, psychosocial stress, 
depression, previous cardiac disease, and ratio of apoB and apoA-I account for 90% of 
the risk (population attributable risk) of stroke 43. 
1.4 The genome  
The human genome resides in the nucleus of the cell and are packed into 23 
chromosomes, although a small quantitative of the genome can be found in the 
mitochondria.  The genome comprises of approximately 2,9 billion nucleotides, it can be 
roughly divided into coding genome (genes) and non-coding genome. The coding 
genome (genes) contains codes which are to be transcribed and translated into peptides 
or proteins, the coding genome contribute to approximately 1.5 % of the entire genome 
and the current estimate of  protein coding genes in humans is 20 687. The non-coding 
genome contain genetic segments of diverse functionalities, these include noncoding 
RNA (e.g. transfer-RNA and ribosomal RNA), pseudogenes, introns, untranslated regions 
of mRNA, regulatory DNA sequences, microRNA, repetitive DNA sequences, and 
sequences related to mobile genetic elements.  The vast majority (80.4%) of the human 
genome is believed to participate in at least one biochemical event in at least one cell 
type 44,45.  
 
The human genome is not completely static throughout life but is to some extent plastic. 
Somatic mutations (mosaicism) do occur and the genome consists of mobile elements 46.  
Mobile elements (transposons) are DNA sequences that have the ability to integrate into 
the genome at a new site within their cell of origin 45,47, however most transposons are 
inactive, only less than 0.05% of all transposons are considered to be active and can 
jump from one genomic region to another.  
 
It is important to note that genes are not solely responsible for phenotypic variation and 
evolution, the non-coding genome also plays an important role. Indeed, the majority 
(above 90%) of trait-associated variants emerging from genetic association studies 
resides within non-coding genomic sequences. Much of the results points towards the 
involvement of genetic variants in transcriptional regulatory mechanisms, including 
variation of promoter and enhancer elements 48. Furthermore, both microRNAs and 
retrotransposons have been suggested to be involved in complex biological processes 
such as human brain development and evolution 49,50. 
Variation in genome can be measured by single nucleotide polymorphisms, insertions, 
deletions, copy number variations and chromosomal rearrangements. Genetic 
variations do however not necessarily result in a change in protein or in gene regulation 
51-53. In order to give a big picture overview of genetic variation examples of genomic 
comparisons between species and within species are presented further on in this 
section. The closest genetic relatives of humans are the bonobo and the chimpanzee. On 
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average, the genetic regions (sex chromosomes not included) in the bonobo genome 
have been found to be approximately 98.7% identical to corresponding sequences in the 
human genome 54. The sequence of the chimpanzee genome has roughly 95 % similarity 
with the human genome sequence 55. Human to human genomic similarity has been 
estimated to be about 99.5% similar, in other words there is 0.5% dissimilarity between 
the human genome of one individual to another 56. Genetic variation among humans is 
thus not large and most of the variation is located in the non-coding genome, besides all 
genetic variation does not necessarily contribute to phenotypic variation. However, it is 
of importance to discover the proportion of the genetic variation that does result in 
phenotypic variation. Identification of such genetic variants may promote greater 
understanding of biological pathways underlying development of various diseases.  
1.5 Biology of depression 
The studies III and IV pertaining to this PhD thesis investigated the relationship 
between depression and CVD development. In this section hypotheses on the etiology of 
depression and its link to CVD will be discussed.  According to the World Health 
Organization, in the year 2004 depression was the third leading contributor to the 
disease burden worldwide 57. In Sweden, the prevalence of depression is high, especially 
among elderly in which 12-15% are affected by depression 58. The etiology of 
depression is idiopathic, the diagnosis is subjective and rests on documentation of a 
certain number of symptoms that significantly impair functioning. Accordingly, 
depression can be viewed as a condition consisting of various diseases of diverse causes 
59. Nevertheless, there are many proposed hypotheses on the etiology of depression, a 
number of them are briefly discussed in this section.  
Monoamine hypothesis 
One of the most known hypotheses regards disturbances in the system of monoamine 
transmissions in the brain. The major types of antidepressants (selective serotonin 
reuptake inhibitors and tricyclic antidepressants) act through increasing certain 
monoamine transmissions in the brain. The affected monoamines are serotonin and 
norepinephrine, it is thus thought that depletion of these monoamines increases the 
predisposition to depression 60. However, it usually takes weeks of treatment before 
mood-enhancing effects of antidepressant are initiated and the remission rate of 
antidepressants is not high which bring uncertainty to the monoamine hypothesis. 
Neuroendocrinology 
Hypothalamic-pituitary-adrenal (HPA) axis is a neuroendocrine system which controls 
the secretion of several hormones and consequently many biological processes, it is 
well-known for being involved in stress reactions 61. Glucocorticoid levels, which are 
regulated by the HPA axis, have been shown to be raised in depressed patients. Physical 
and psychological stress increase levels of serum glucocorticoids.  Depression has been 
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linked to metabolic disturbances such as diabetes, increased glucocorticoid levels can 
induce insulin resistance. Patients with Cushing’s syndrome have abnormal cortisol 
levels and they display depressive symptoms 62. 
Immune system  
In animal studies cytokines have been reported to influence depressive like behavior 
63.Numerous studies have demonstrated depressed patients to have activated 
inflammatory response displayed through higher levels of cytokines, CRP, platelet 
activation molecules and adhesion molecules 64. But some studies have failed to 
establish associations between inflammatory markers and depression 65,66.  
Vascular depression and poststroke depression  
Vascular risk factors (such as hypertension and metabolic syndrome) and cerebral 
small vessel disease (infarcts and white matter lesion) have been shown to be 
associated with depression, more specifically depression among the elderly. Due to 
these findings the term   “vascular depression” was coined which describes a subtype of 
depression affecting elderly individuals with vascular disruptions 67-69. A systematic 
review investigating the association between vascular complications and late life 
depression could lend support to the vascular depression hypothesis, however only 
studies with cross sectional design were included in the meta-analysis 70. It is important 
to stress that some studies on the depression-stroke link have found the association to 
be larger among those with early onset depression 71,72 (as opposed to late life 
depression). It could also be worth mentioning that this opposite trend could also be 
detected when investigating the study population used in study III pertaining to this 
thesis (supplementary tables S1 and S2). 
Many observational studies have reported an association of depression occurring after 
stroke onset, this syndrome is called poststroke depression. It is expected that around a 
third of stroke patients will suffer from subsequent depression 73. It has been suggested 
that poststroke depression is caused by lesions in certain brain regions 74. Poststroke 
depression thus lends support to the notion of vascular depression. 
The link between depression and CVD 
Depression has been found to be associated with both CHD and stroke development 
according to two comprehensive meta-analyses 75,76. It is not clear if depression in itself 
causes CVD or if the association is explained by other risk factors. A previous study 
found the association to be explained by behavioral mediators, namely physical activity, 
smoking and medication adherence 77. Other explanations that have been suggested 
include immunological mechanisms, mechanisms of stress response, excessive platelet 
activity and toxicity of antidepressants 78-81. A modest shared genetic vulnerability 
between major depression and coronary artery disease status has previously been 
reported 82. Antidepressants use and its relationship with CVD risk has been examined 
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in several former studies, and the results have been conflicting. Some studies have 
shown that use of antidepressants increases the risk of CVD, even after adjusting for 
depression 83-86, and some have reported the antidepressants to be CVD protective 87-90, 
while some studies have reported null findings 91,92.   
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2 Aims of the thesis 
The overall aim was to gain a comprehensive understanding of the epidemiology of 
well- established and promising risk factors for cardiovascular disease. Both genetic and 
environmental contribution to cardiovascular disease was considered. 
More specifically, the objectives of the four separate studies were as follows: 
- Study I: To estimate the variance components of HDL, LDL, total cholesterol, 
apoA-I, apoB, triglycerides, glucose, HbA1c, and CRP levels. 
- Study II: To investigate to what degree the levels of the novel CVD biomarkers 
Lp-PLA2 and anti-PC are affected by genetic and environmental factors 
- Study III: To determine if clinical depression diagnosis and use of 
antidepressants are associated with CVD morbidity and mortality. Further, to 
examine if the associations are more specific for CHD or ischemic stroke.  
- Study IV: To assess the association between depression and stroke after 
controlling for well-established stroke risk factors 
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Figure 2. Timeline depicting the collection of data and the establishments of cohorts and registers over the past decades. These are the 
registers and cohorts that have been the source of data for the four constituent papers of the PhD thesis.  
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3 Overview of study populations and registers                 
3.1 Swedish Twin Registry 
The Swedish Twin Registry (STR) is one of the world’s largest twin resources, currently 
containing 194,842 twins born between 1886 and 2008. STR obtains information on 
twin births occurring in Sweden from the National Board of Health and Welfare. It was 
established in the 1950’s with a primary focus on epidemiological studies on CVD and 
cancer.  The registry consists of three birth cohorts, two of these cohorts (the birth 
cohorts 1886-1925 and 1926-1958) have been used as study material for this PhD 
project. STR receives regular updates from health registers including the national 
patient register, the medical birth register, the prescribed drug registry, and the causes 
of death register. The twins have also been contacted in several additional waves with 
requests to participate in questionnaire/interview studies covering a broad selection of 
exposures, behavior and medical information. For the majority of same-sex twins in the 
STR, zygosity has been determined based on self-reported childhood resemblance, 
however DNA-based zygosity is available for 13% of all same-sexed twins in STR. Tests 
of the validity of similarity-based zygosity assignment by looking at genetic markers 
have overall yielded an accuracy estimate of around 98% among adults 93-95. 
SALT 
The study participants were identified from the population-based Swedish Twin 
Registry and had all participated in a computer assisted telephone interview called 
SALT (Screening Across the Lifespan Twin Study) conducted between 1998 and 2002. 
All screening data were collected over the telephone by trained interviewers with 
adequate medical background.  Information on lifestyle and habits including 
educational level and smoking habits was collected. Special emphasis was put on 
diagnostic items that could determine whether a twin was likely to have a disease 
(rather than simply asking the twin whether they have a disease) 93,95. The 11-item CES-
D was administered during the SALT interview, which is a screening tool recommended 
to be used to measure current depression among elderly. A list of common prescriptions 
and non-prescription medication use was also recorded. A total of 44 826 individuals 
born before 1959 participated in the interview. Self-reported weight and height was 
available from the interview and BMI could be derived from these variables.  
TwinGene 
Twingene is a large population-based study on Swedish elderly twins born between 
1911 and 1958. The study participants had previously taken part in the SALT interview. 
To be included in TwinGene, both twins within a pair had to be alive. In total, 12,647 
individuals participated by donating blood to the study, and by answering extensive 
questionnaires about life style and health between 2004 and 2008. A total of 22,390 
twins were invited to the study, thus the overall response rate was around 56%. The 
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participants were asked to make an appointment at their local health-care facility on 
Monday to Thursday mornings (not the day before a national holiday), to ensure that 
their blood sample would reach the KI Biobank in Stockholm the following day by 
overnight mail. A range of CVD blood biomarker levels were assessed from the blood 
samples, including lipids and inflammatory markers. Sampling and clinical blood test 
procedures have been described elsewhere 96. Twingene has been linked to the Swedish 
national patient register, the causes of death register, and the Swedish psychiatric 
registry. The study was approved by the regional ethical review board at Karolinska 
Institutet and all participants gave informed consent. Study participants’ weight and 
height were measured at the local health care facility, BMI was derived from these two 
variables. Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were 
assessed by taking two measurements after five minutes rest. Age had a pronounced 
effect on the propensity to participate with a peak in participation for individuals born 
between 1936 and 1940, and therefore likely to comprise of recent pensioners. Sex did 
not affect participation since participation rates among males and females were very 
similar 94. 
3.2 National Patient Register 
The national patient register (NPR) in this case represents the inpatient register, which 
includes all hospital admissions that entailed at least one overnight stay, and the 
outpatient register which includes diagnoses registered during non-private specialized 
care. The inpatient register was established in 1964 and has full coverage since 1987. 
Currently, the coverage of the inpatient register is nearly 100%, while for the outpatient 
register it is about 80%. In the outpatient register, data from the private care are 
missing but the coverage of data from public care is almost 100%. Surgical day care 
procedures have been reported to the national patient register from 1997 and onwards, 
and since 2001 it is mandatory for counties to report outpatient physician 
visits. Diagnoses in the national patient register are coded according to the international 
classification of disease (ICD) system. The recording of the hospital admissions include 
a primary diagnosis and up to eight additional diagnoses as well as surgical procedures. 
The Swedish personal identity number enables the linking of registries. 97 
 
According to validation studies, the positive predictive values for heart failure, stroke 
and myocardial infarction in the inpatient register are in the range of 69-100% . 
Unfortunately, no validation studies have been undertaken to assess the validity of 
unipolar depression diagnoses. An increasing number of patients have been treated at 
the outpatient care over time. This might have led to a decreased sensitivity of the 
inpatient register in recent years for some diseases 98. It has been reported that at least 
in Stockholm county there has been a shift from inpatient care towards more outpatient 
care for psychiatric patients in the 1990’s 99.   
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3.3 Causes of Death Register 
The causes of death register contains information on all deaths among Swedish 
residents, it was established in 1961 and is updated every year. The causes of death are 
classified according to the ICD. The register includes information on the main 
underlying cause of death as well as contributing causes of death. In some cases the 
deaths reported do not have information available from the death certificate, and thus 
the death is reported without a cause of death, in 2011 1.8% of the deaths reported 
lacked information on the cause of death 100.  
3.4 The Prescribed Drug Registry 
The national prescribed drug registry (PDR) records all prescribed drugs dispensed at 
pharmacies all around Sweden. Drugs that have been prescribed at hospital settings are 
not included in the register.  The registry contains information on the identity of the 
drug according to the Anatomical Therapeutic Chemical (ATC) Classification System, the 
amount of drug articles (packages), price, prescription date etc. 101.  The registry 
contains information on prescriptions on some regions in Sweden from June 2004, and 
has full, national coverage since around January 2006. 
3.5 Swedish Psychiatric Registry 
Swedish Psychiatric Registry covers all psychiatric hospital discharges between the 
years 1963 and 1983. This registry contains up to six recorded diagnoses according to 
ICD-8. It includes information on patients receiving psychiatric treatment at all 
psychiatric hospitals in Sweden as well as all in-patient psychiatric departments of 
general hospitals 102. 
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4 Overview of methods 
4.1 Twin modeling 
One of the most popular twin methodologies to be utilized in epidemiological research 
is variance partitioning (heritability analysis). It is a method used to disentangle the 
relative contribution of genetic and environmental factors underlying a trait variance 
(total phenotypic variance). The methodology makes use of the genetic correlation 
between twins. Monozygotic (MZ) twins share 100% of their segregating genes (genetic 
correlation equals 1) while dizygotic (DZ) twins share roughly 50% of their segregating 
genes (genetic correlation equals 0.5). Studies examining genetic data have both 
supported the MZ genetic correlation 103 and refuted it 104.  In addition, it is assumed 
that MZ twins as well as DZ twins share their intrauterine and upbringing household 
environment (the period in life in which they are reared together) to the same extent. 
This assumption is called the equal environment assumption. In short, any trait 
similarity within a twin pair measured by intra-pair trait correlations (r = 
 (   ̅)(   ̅)
√ (   ̅)  (   ̅) 
) is due to either genetic or shared environmental factors. Trait 
dissimilarities within a twin pair on the other hand are due to unique environmental 
factors 105. 
Below are equations for calculating broad-sense heritability component (h2), additive 
genetic component (a2), dominant genetic component (d2), shared environmental 
component (c2) and unique environmental component (e2) in twin studies. 
rMZ= a2 + c2 
rDZ= a2 /2+ c2 
a2=2(r(MZ)-r(DZ)) 
d2=4(r(MZ)-r(DZ)) 
c2=rMZ- a2 
h2= a2 + d2 
h2 + c2 + e2 = 1 
rMZ + e2 = 1 
e2=1-r(MZ) 
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Additive genetic variation 
Additive genetic effect means that the overall genetic variation contributing to the 
phenotypic variation is the sum of all the individual effects of multiple loci (genotypes).  
Under an additive genetic model, it is assumed that there is no interaction between the 
alleles within a locus or between loci 105. However, according to Falconer & Mackay 
additive genetic variance should not rest on the assumption of purely additive gene 
effects (i.e. that the genes act additively with absolute absence of interactions) since 
additive genetic effects can actually only be measured by molecular data 106  
Non-additive genetic variation 
Non-additive genetic variance may enable the measurement of the portion of 
phenotypic variance which is due to epistatic interactions (gene-gene interactions) and 
dominance deviations (interactions within locus). In other words, epistasis depicts 
situations in which the total genetic effect is not the sum of all the individual effects 
across multiple loci and dominance genetics means that the total effect of a locus does 
not equal the sum of the effects of the two alleles in that particular locus.  It is very 
difficult to estimate epistasis in a classical twin setting, if the MZ correlation is much 
larger than the DZ correlation it could be indicative of epistasis 105. 
Multivariate analysis 
It is possible to conduct variance partitioning of multiple traits. i.e. to analyze if the 
covariance of two or more traits  can be attributed to common genetic or environmental 
variance. In study II multivariate variance partitioning was carried out implementing 
the cholesky decomposition model, in addition to obtaining a bivariate heritability 
estimate, a genetic correlation as well as unique environmental correlation was 
calculated. The genetic correlation indicates the extent to which genetic influences in 
one phenotype overlap with those of another phenotype.  The genetic correlation could 
imply pleotropic genetic regulation contributing to multiple phenotypes. The bivariate 
heritability, also referred to as the standardized genetic covariance, reflects the genetic 
component of the total phenotypic correlation between two traits. The bivariate 
variance component estimates are achieved through calculating intra-individual within-
trait correlations and comparing them to cross-twin cross-trait correlations 105.  
Key assumptions in twin studies 
Equal environment assumption 
 It is debated whether indeed MZ twins and DZ twins share similar degree of shared 
environment (intrauterine and upbringing household environment). MZ twins are often 
monochorionic twins i.e. they share the same placenta while DZ twins almost always 
have separate placentas and are thus dichorionic twins. There can also be competition 
between the twins in-utero and this could potentially affect the MZ twins more strongly 
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107. MZ twins might spend more time together compared to DZ twins later in life, this 
was investigated in study I 96. Although many studies have pointed out differences in 
levels of shared environment for MZ and DZ twins, none of these differences have 
shown to have any substantial effect on heritability estimates.  
Gene-environment interaction 
 It has been shown that gene expression variation can depend on environmental 
conditions 108, as such it could be plausible that individuals with similar genotypes who 
have been exposed to different environments will exhibit differences in the affected 
phenotype. But the variance due to gene-environment interactions is thought to be 
included in the environmental variance component 106.  
Assortative mating 
When individuals who resemble each other regarding certain phenotypes (for instance 
physical appearance) mate it results in assortative mating 107. If the assortative mating 
(phenotypic similarity) is due to genetic similarity than the offspring of this mating 
might become more genetically similar. As a consequence the genetic correlation 
between DZ twins might be higher than 0.5, and thus one of the fundamental 
assumptions in twin modeling will be violated.  
Direct effects in multivariate analyses 
 There is a concern regarding the cholesky model that it relies on the assumption that 
there is no direct effect of one phenotype to the other (meaning the effect is not due to 
shared genetic or environmental factors). If this assumption is violated both the genetic 
correlation and the environmental correlation will be inflated 109. 
4.2 Linear regression 
Linear regression is applied when dealing with a continuous outcome variable ( ) is 
expected to be dependent on one or several exposure variables ( ). The outcome 
variable needs to have a normal distribution, with an expected value        and 
variance σ2.  The equation of a simple linear regression line is  
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where regression parameters 
    
 (   ̅)(   ̅)
 (   ̅) 
 
     ̅       ̅ 
and   is the error term 
 
Linear regression rest on the assumptions that the errors terms have the same variance 
for all observations, and that for any level of  ,   is normally distributed 110. 
4.3 Cox proportional hazards regression 
The cox proportional hazards model is used for time-to-event analysis. The hazard rate 
(how long time it takes for an event to occur) is measured in the exposed and non-
exposed group and the hazard ratio (the ratio of the hazard rates) informs if the hazard 
rate of the event occurring is higher or lower in the exposed group in relation to the 
unexposed group.  It is a semi-parametric model since the underlying function of the 
baseline hazard function is unknown and thus lacks a mean and variance. It uses the 
partial likelihood function 111. The model relies on the proportional hazards assumption, 
the assumption necessitates that the hazard rate in one level of a covariate in the model 
should be a constant multiple of the corresponding hazard rate of that covariates 
baseline level over time.  
Time varying covariates  
In cox regression, partial likelihood is used, a part of the likelihood is estimated each 
time an event occurs. In a cox model which incorporates time varying covariates, you 
allow the status of the covariate to change between the events, i.e. it considers intra-
individual variation over time.  An individual’s risk can thus change over time due to 
change in covariate status, the individual can for instance go from unexposed to 
exposed. 
4.4 Clustered data 
In statistical analyses one of the most fundamental assumptions is that the observations 
in a model are independent from each other. Hence, if the observations are to some 
extent correlated, which is the case when utilizing data from twin pairs, this crucial 
assumption is violated. When assuming that the model has more independent 
observations than what it really does the power can be overestimated leading to too 
narrow confidence intervals of the regression parameters. Different statistical 
techniques can deal with correlated data, and often when considering the 
interdependence of the observations the standard errors become larger.  
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Robust sandwich variance estimator 
The robust sandwich variance estimator can be used to measure the standard errors 
when the errors do not have the same variance for all observations or when the 
observations are not independent from each other 112. Hence it can be implemented 
when dealing with clustered data. The robust sandwich variance estimator allows for a 
flexible model approach since it can handle structure of covariance-variance matrices 
that are misspecified. 
Generalized estimating equations 
One popular method to handle clustered data is by utilization of generalized estimating 
equations (GEE), since it will not rely on assumptions about the distribution of the error 
terms of your model 113. GEE is flexible, the model allows you to specify a link function 
and can handle distributions such as normal, binomial and poisson. It uses the quasi-
likelihood function, however the parameters produced by a GEE model has almost the 
same precision as those produced by maximum likelihood models 111. GEE can use the 
robust sandwich variance estimator to calculate the standard errors.  
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5 Study summaries 
5.1 Study I 
In this study we aimed to estimate additive and non-additive genetic influences for HDL, 
LDL, total cholesterol, apoA-I, apoB, triglycerides, glucose, HbA1c, and CRP in a large 
sample of participants belonging to the Swedish Twin Registry. This was the largest 
twin study to date for several of the investigated biomarkers, providing data with better 
power than has previously been possible. Furthermore, since all the biomarkers have 
been assessed at the same occasion of all participants, direct comparisons between the 
estimates were facilitated. 
Materials and methods 
Study material was obtained from the TwinGene project which is a population-based 
study of Swedish twins born between 1911-1958, who were contacted and tested 
between 2004 and 2008. Informed consent was obtained from all participants. The 
participants were asked to make an appointment at their local health-care facility. The 
participants were instructed to fast from 8 PM (20:00) the previous night. A total 
volume of 50 ml of blood was drawn from each individual by venipuncture. 
Assessment of serum samples 
Clinical blood chemistry assessments were performed by the Karolinska University 
Hospital Laboratory. Levels of HbA1c were measured by a high-liquid performance 
chromatography separation technique. Levels of the other biomarkers were determined 
by Synchron LX systems (Beckman Coulter). 
LDL levels were derived through the friedewald formula 114. If you have measurements 
of total cholesterol, HDL and triglycerides this can be estimated by the following 
formula   HDL = Total cholesterol – LDL – 0.45*Triglycerides, this formula can only be 
applied if plasma triglyceride levels are below 4.52 mmol/L.  
Statistical analyses 
Data handling and calculation of descriptive statistics as well as correlation coefficients 
were performed in SAS version 9.1 (SAS Institute, Cary, NC, USA). A variance component 
maximum likelihood method was implemented for estimation of variance components 
for each phenotype, using the Mx statistical program 115. Univariate twin analyses were 
conducted in which the variance of the adjusted phenotypic values was divided into 
additive genetic effects (A), dominant genetic effects (D), shared environmental effects 
(C), and unique environmental effects (E). Scripts downloaded from the GenomEUtwin 
Mx-script library (http://www.psy.vu.nl/mxbib/) 
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Results 
General characteristics of the study population, stratified by gender are summarized in 
Table 1.  
Table 1 General characteristics of study participants. 
 Men Women 
Na 5327 6421 
Age (mean ± sd) 66.6 ± 8.7 65.9 ± 8.9 
Weight (Kg, mean ± sd) 81.3 ± 12 68.3 ± 12 
BMI (Kg/m2, mean ± sd) 26.2 ± 3.5 25.7 ± 4.3 
Individuals receiving statins (Na) 744 (14%) 601 (9%) 
Individuals receiving fibrates (Na) 9 (0.2%) 3 (0.05%) 
MZb (Na) 1281 (44%) 1656 (56%) 
SSDZc (Na) 1817 (43%) 2376 (57%) 
OSDZd (Na) 2175 (48%) 2346 (52%) 
Unknown zygosity (Na) 54 (0.56%) 43 (0.44%) 
aNumber of individuals, bMonozygotic, cSame-sexed dizygotic, dOpposite-sexed 
dizygotic 
Table 2 shows the variance component decomposition with 95% confidence intervals 
(CI) from the ADE and AE models for all phenotypes.  Additive genetic variance 
component was estimated to 0.66 for HDL, 0.64 for apoA-I, 0.48 for apoB, 0.50 for total 
cholesterol and 0.54 for TG. For these traits the dominant genetic component was not 
significant. Both additive and dominant genetic component were significant for LDL, 
glucose, and HbA1c. For LDL, additive and dominant genetic effects were estimated to 
0.35 and 0.18, respectively. For glucose the corresponding estimates were 0.22 and 
0.31, while for HbA1c additive genetic component was 0.16 and dominant genetic 
component was 0.55. In the ADE model the additive genetic component for CRP was not 
statistically significant, 0.13 (95% CI 0.00-0.28) while the dominant genetic component 
was estimated to 0.30 (0.12-0.46). Effect of non-shared environment was significant for 
all phenotypic traits.   
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Table 2 Parameter estimates with 95% confidence intervals for additive genetic (a2), 
dominant genetic (d2) and non-shared environmental (e2) variance components of age and 
sex adjusted trait levels in AE and ADE models.  
Phenotype Model a2 (95%CI) d2(95%CI) e2(95%CI) 
HbA1c ADE 0.16 (0.03-0.29) 0.55 (0.55-
0.68)    
0.29 (0.27-0.32)     
apoA-I AE 0.64 (0.64-0.67) - 0.36(0.33-0.37) 
apoB AE 0.48 (0.44-0.51) - 0.52 (0.49-0.56) 
HDL AE 0.66 (0.63-0.68) - 0.34 (0.32-0.37) 
LDL ADE 0.35 (0.21 -0.49) 0.18 (0.03- 
0.33)  
0.47 (0.44 - 0.51)   
TG AE 0.54 (0.51-0.57) - 0.46 (0.43-0.49) 
Total cholesterol AE 0.50 (0.46-0.53) - 0.50 (0.47- 
0.54)) 
Glucose ADE 0.22 (0.08-0.35) 0.31 (0.16-
0.46) 
0.47 (0.44-0.56) 
CRP ADE 0.13 (0.00-0.28) 0.30 (0.12-
0.46) 
0.57 (0.53-0.62) 
aPearson’s correlation coefficient for MZ twins, bPearson’s correlation coefficient for 
SSDZ twins, cPearson’s correlation coefficient for OSDZ twins.      
Since violation of the assumption of equal shared environment between MZ and DZ (i.e. 
MZ twins are exposed to more trait-relevant shared-environmental influences than DZ) 
would mimic genetic dominance, we investigated if discrepancies in reported contact 
frequency (i.e. the frequency by which the twins in a pair met in person) between MZ 
and DZ twins were present. MZ twins reported greater contact frequency than DZ twins, 
mean contact level was 3.00 for MZ twins while it was 2.57 for DZ twins (t-test, 
p<0.0001). Next, we investigated if contact frequency also was correlated with 
similarity in trait levels by computing the rank-order correlation (Spearman) between 
contact frequency and the absolute intra-pair difference in adjusted trait-levels. None of 
the zygosity specific correlations of trait difference and twin contact frequency reached 
significance except for difference in HDL among MZ twin pairs ( r=-0.058, p=0.04 ).  
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The age at separation from co-twin (i.e. time shared same household environment) is 
also a measure of the degree of shared-environmental influences. Results showed that 
mean age at separation was significantly higher for MZ than for DZ twins, 19.7 years and 
18.4 years, respectively  (t-test, p<0.0001). For each separate zygosity strata the 
relation between absolute intra-pair difference in adjusted trait levels and age at 
separation was insignificant for all traits except apoA-I in MZ twins (r=-0.061, p=0.04). 
Discussion 
Our results for additive genetic effects for HDL, apoA-I, total cholesterol, and TG are 
consistent with what have been demonstrated in previous publications 116-131. In 
addition, the contribution of non-shared environment was significant for all traits, 
which is also in agreement with what has previously been found. Here, we show for the 
first time significant effects of genetic dominance for LDL, CRP, glucose, and HbA1c in a 
population based twin sample. The reason for the novel findings of dominant genetic 
effects may be because of the enhanced power of the large and homogenous sample in 
our study compared to previous ones, enabling us to detect weaker variance 
components underlying the phenotypic traits. The high age of the study participants 
might also have been a contributing factor, leading to decreased influences from shared 
familial environment. In the case of CRP, additive genetic effect was found insignificant. 
This should not be taken as evidence for an absence of influences from additive genes 
(which appears biologically implausible for CRP) but indicates insufficient statistical 
power or some source of bias. Since variance component estimates are specific to the 
studied population, it is important to bear in mind that the obtained results not 
necessarily are representative of other populations or ethnic groups.  
There appears to be no influence from shared environmental factors in this population. 
In the classical twin design comparing variance/covariance structures in MZ and DZ 
twins reared together it is not possible to model the effect of shared environment and 
dominance genetics simultaneously. Therefore, both influences may co-exist but their 
influences are not estimable in the same model. Another source of bias could come from 
violations of the assumption of equal importance of shared environmental influences 
between MZ and DZ twins. 
 
By using data on contact frequency and age at separation available for a majority of the 
study participants, we demonstrated that there was evidence for differences in amount 
of shared environment between the zygosity classes. Even if MZ twins report 
significantly higher contact frequency and higher age at separation compared to DZ 
twins, we only found weak evidence for this to have an impact on twin trait similarity  
and more so this was only shown for HDL and apoA-I.  
 
Large scale genetic association studies have been conducted to identify genetic variants 
influencing blood lipid levels. A genome-wide association study by Teslovich et al could 
23 
 
find 95 genetic variants significantly associated with TC, HDL, LDL, or TG. Some of these 
genetic variants were also associated with coronary artery disease.  However, the 
genetic variants had small effect sizes and could only explain around 25-30% of the 
genetic variance of each lipid trait 132. 
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5.2 Study II 
 
The aim of this study was to examine how variation in anti-PC levels and Lp-PLA2 
activity is explained by genetic and environmental effects and how these effects are 
shared with other established CVD biomarkers.  
Materials and methods 
 
The TwinGene project was used as study material. In total, 12591 individuals 
participated by donating blood to the study, and by answering questionnaires about life 
style and health. Detailed procedures for blood sampling have been previously 
described 96.  
 
Measurements of Lp-PLA2 and anti-PC 
Lp-PLA2 activity has been measured in 1600 individuals. Lp-PLA2 activity was measured 
from plasma stored at –80°C in 96-well plates. Samples were measured in duplicate. 
Pooled human EDTA plasma from 20 normolipidemic human subjects served as an 
internal standard for all measurements. Lp-PLA2 activity is expressed in nmol of 
degraded PAF per min per ml of plasma. The within-assay variability was ≤ ± 5% % 
133,134.  
 
IgM anti-PC levels were measured in a subset of 2036 TwinGene participants using an 
indirect non-competitive enzyme immunoassay (CVDefine ®, Athera Biotechnologies AB, 
Stockholm, Sweden) according to the manufacturer’s instructions. The IgM anti-PC 
levels were expressed as arbitrary units (U/ml) estimated from a six point calibrator 
curve containing IgM anti-PC levels ranging from 0 to 100 U/ml 34. 
 
Data handling and calculation of descriptive statistics as well as correlation coefficients 
were performed in SAS version 9.2 (SAS Institute, Cary, NC, USA). The proc genmod 
procedure (which applies generalized estimating equations) in SAS was implemented to 
perform linear regressions. A variance component maximum likelihood method was 
implemented for estimation of variance components for each trait, using the Mx 
statistical program 115. Univariate twin analyses were conducted in which the trait 
variance was divided into additive genetic effects (A), dominant genetic effects (D), 
shared environmental effects (C), and unique environmental effects (E).  Bivariate 
Cholesky models were analyzed in Mx for correlated traits, to partition the phenotypic 
correlation into A, C and E. 
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Results 
 
The general characteristics of the study sample and distributions of the phenotypes by 
zygosity group are described in Table 3. 
 
Table 3 General characteristics of the study population.  
 
 
Table 4 shows the variance component decomposition with 95% confidence intervals 
(CI) from the ACE and AE model for Lp-PLA2. The AE model was favored by the principle 
of parsimony since the 2 test was not significant. According to AIC, the ADE model was 
 MZ SSDZ OSDZ 
Variable N Mean (std 
dev) 
N Mean (std 
dev) 
N Mean (std 
dev) 
Age (years) 1034 78.7 (4.05) 542 81.5 (4.11) 460 79.3 (2.38) 
Lp-PLA2 
(nmol/ml/min)  
779 61.3 (20.8) 434 62.9 (23.5) 374 64.8 (24.5) 
Anti-PC (U/ml)  1034 89.1 (150) 542 72.1  (118) 460 74.6 (110) 
CRP (mg/L) 980 3.81 (5.98) 515 4.37 (8.62) 445 3.92 (5.87) 
ApoA1 (g/L) 1018 1.58 (0.30) 537 1.59 (0.30) 456 1.57 (0.29) 
ApoB (g/L) 1018 1.12 (0.26) 537 1.10 (0.25) 456 1.13 (0.27) 
TC (mmol/L) 1018 5.68 (1.15) 537 5.60 (1.17) 456 5.70 (1.27) 
HDL (mmol/L) 1018 1.39 (0.40) 537 1.41 (0.41) 456 1.39 (0.41) 
LDL (mmol/L) 1018 3.68 (1.02) 534 3.58 (1.02) 453 3.67 (1.03) 
TG (mmol/L) 1018 1.38 (0.69) 537 1.37 (0.66) 456   1.40 (0.73) 
Glucose (mmol/L) 1018 5.68 (1.22) 537 5.77 (1.23) 456 5.76 (1.24) 
HbA1c (%) 1017 4.95 (0.65) 534 4.93 (0.69) 455 4.99 (0.73) 
BMI (kg/m2) 1034 26.0 (3.71) 542 25.7 (3.86) 460 25.8 (3.90) 
Weight (kg) 1034 71.9 (12.5) 542 70.2 (12.6) 460 72.9 (13.5) 
WC (cm) 1032 91.6 (11.4) 541 91.1 (11.5) 456 92.7 (11.9) 
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to be preferred over the ACE model for anti-PC. Therefore, ADE and DE models with 
95% CI are reported. Influence from unique environment was significant (p<0.05) for 
both of the traits. Contribution of additive genetic component was found to be 0.34 for 
Lp-PLA2, while the corresponding estimate for anti-PC was non-significant. Even though 
the DE model is to be preferred for the variance component decomposition of anti-PC, it 
is not biologically plausible that dominance genetics would be the sole source for the 
genetic contribution in this case. This is most likely a result from insufficient power, 
nevertheless, the dominance genetic effect is 0.40 for anti-PC. No statistically significant 
evidence for influences of shared-environment was obtained for either of the 
biomarkers. 
Table 4 Parameter estimates with 95% CI for additive genetic (a2), shared environmental 
(c2), dominant genetic (d2) and unique environmental (e2) variance components of age 
and sex adjusted Lp-PLA2 and anti-PC levels. 
N = the number of individuals, r = Pearson’s correlation coefficient, MZ = monozygotic 
twin pairs, SSDZ = same-sexed dizygotic twins, OSDZ = opposite-sexed dizygotic twins. 
Anti-PC levels were correlated with CRP, apoB, TC, HDL, LDL, and Lp-PLA2, however the 
magnitudes of the correlation coefficients were not large enough (r<0.2) for further 
investigations by bivariate variance partitioning. ApoB, TC and LDL were the 
biomarkers most strongly correlated with Lp-PLA2 activity (r>0.2) which motivated 
further attempts to disentangle the contributing components by bivariate analyses 
(data not shown). The genetic overlap (rG) between Lp-PLA2 and the other traits (apoB, 
TC and LDL) was in the range of 0.39-0.46. The corresponding overlap of unique 
environmental factors affecting the traits (rE) varied between 0.44-0.49 (Table 5). The 
covariance component decomposition was relatively similar for all three comparisons. 
Around one third of the total phenotypic correlation between Lp-PLA2 activity and the 
other trait levels appears to be explained by genetic factors.  
 
 
Phenotype 
 
a2 (95% CI) 
 
c2 (95% CI) d2 (95% CI) e2 (95% CI) 
Mx 
Model 
Lp-PLA2 0.34 (0.07-
0.45) 
0.02 (0.00-
0.22) 
- 0.64  (0.55-
0.75) 
ACE 
 0.37 (0.27-
0.45) 
- - 0.63  (0.55-
0.73) 
AE 
Anti-PC 0.05 (0.00-
0.29) 
- 0.34 (0.09-
0.44) 
0.61  (0.56-
0.66) 
ADE 
 - - 0.40 (0.34-
0.44) 
0.60 (0.56-
0.66) 
DE 
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Table 5 Genetic and unique environmental correlations and bivariate variance 
components decomposition with 95% CI  
Biv h2 = Bivariate additive genetic component 
Biv e2 = Bivariate unique environmental component 
Discussion 
A heritable component could be found for both Lp-PLA2 and anti-PC. For Lp-PLA2, 0.37 
of the total variance in enzymatic activity could be attributed to genetic variance. The 
highest cross-trait correlation was found for Lp-PLA2 and LDL, apoB and TC were also 
moderately correlated with Lp-PLA2. Further dissection of the covariance between Lp-
PLA2 and LDL revealed a genetic co-regulation explaining 36% of the total phenotypic 
correlation. Thus, 64% of the phenotypic correlation observed is explained by other 
factors.  Lipid-lowering drugs with known reducing effects on LDL levels could also give 
concomitant reduction in Lp-PLA2 activity. Lipid-lowering drugs may hence represent 
one of the co-regulating environmental factors.  A previous report demonstrated that 
atorvastatin significantly reduced Lp-PLA2 activity compared with placebo, even after 
adjusting for LDL 135. 
 Genetic variants in the APOE/APOC1 region have been associated with TC, LDL and 
apoB, and have also been found to be significantly associated with Lp-PLA2 activity 
136,137. A recent study showed that several genetic variants related to LDL levels in 
humans are also associated with Lp-PLA2 activity 138. A former study pointed out a 
genetic region contributing to the variance in both LDL level and Lp-PLA2 activity by 
genome-wide linkage analyses in baboons corresponding to the genetic region 2p24.3-
p23.2 in humans 139. These findings suggest that there are genetic regions that could 
possibly harbor genetic variants exerting pleiotropic effects on Lp-PLA2 activity and 
LDL, TC as well as apoB. 
Our heritability estimate for Lp-PLA2 activity is lower than previously reported. Two 
former studies on the heritability of Lp-PLA2 activity estimated the genetic component 
to be 0.62 and 0.54, respectively 29,140. In the first study, Guerra et al. utilized 60 nuclear 
families (n=240) looking at parent-offspring Lp-PLA2 activity relationship to measure 
heritability. In the second study based on 54 twin pairs, a genetic estimate of 0.54 with a 
p-value of 0.066 was reported 140. A possible explanation for lower heritability estimate 
may be due to imprecision caused by the smaller sample sizes in the previous studies. 
Phenotypes rG (95% CI) rE (95% CI) Biv h2 (95% CI) Biv e2 (95% CI) 
Lp-PLA2-ApoB 0.39 (0.20-0.76) 0.49(0.41- 0.56) 0.33 (0.16-0.48) 0.67 (0.52-0.84) 
Lp-PLA2-TC 0.45 (0.24-0.89) 0.44 (0.35-0.51) 0.35 (0.18-0.50) 0.65 (0.50-0.82) 
Lp-PLA2-LDL 0.46 (0.27-0.83) 0.47 (0.39- 0.55) 0.36 (0.21-0.50) 0.64 (0.50-0.79) 
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Our study population consists of a much larger sample size, thus the precision of the 
parameter estimates is higher. 
 
This was the first time heritability analysis was conducted for anti-PC. A genetic 
component of 0.40 was observed for anti-PC levels. For anti-PC, the cross-trait 
correlations were weak (the highest correlation of 0.08 was observed together with Lp-
PLA2, LDL and TC). This could indicate that anti-PC is an independent biomarker for 
CVD, with a regulation that differs from the other CVD biomarkers assessed in this 
study. It should be mentioned that antibodies generally have complex regulations and 
functions and can undergo alterations in properties due to immunoglobulin class 
switching 141.  
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5.3 Study III 
In this study we aimed to determine if clinical depression diagnosis and use of 
antidepressants are associated with CVD morbidity and mortality in a large population-
based cohort. Further, we examine if the associations were more specific for CHD or 
ischemic stroke.  
Materials and methods 
The study participants were identified from the population-based Swedish Twin 
Registry and had all participated in a computer assisted telephone interview called 
SALT (Screening Across the Lifespan Twin Study) conducted between 1998 and 2002. 
Information on lifestyle, habits and health was collected. A list of common prescriptions 
and non-prescription medication use was also recorded. In total, 36,654 of the SALT 
participants were alive and free of CVD at baseline and included in this study.  SALT has 
been linked to the national patient register, the causes of death register, the Swedish 
psychiatric registry and the prescribed drug registry.  
Information on exposures and outcomes 
Information on depression and CVD diagnoses were obtained through linkage to the 
national patient register. The national patient register in this case represents the 
inpatient register, which includes all hospital admissions that entailed at least one 
overnight stay, and the outpatient register which includes diagnoses registered during 
non-private specialized care. 
The following diagnoses were used to define clinical depression; mild, moderate, severe 
depression with or without psychosis; atypical depression; recurrent depressive 
disorder with or without psychosis; other recurrent depression; dysthymia and mixed 
depression and anxiety. The following ICD codes were used; (ICD-10; F32.0-3, F32.8-9, 
F33.0-4, F33.8-9, F34.1 and F42.1), (ICD-9; 296C-D, 296W, 298A, 300E, 309A-B, 311X), 
(ICD-8; 296.00, 298.00, 300.40-41, 790.20), and (ICD-7; 314.99). In total, 1080 
individuals were identified as receiving at least one diagnosis of depression.  
CVD events were identified through ICD and surgical codes. The following ICD codes 
were used to identify cases of CHD (MI and unstable angina), heart failure, ischemic 
stroke and TIA; (ICD-10; I200, I21-2, I50, I63-4, G45), (ICD-9; 410-1, 433-6, 428), (ICD-
8; 410-1, 432-6, 427), (ICD-7; 420, 332, 454, 434).  In all, 2044 of the participants had 
suffered at least one incident CVD event.  
Antidepressant use was identified through at least one prescription of the atc-code 
“NO6A” from the prescribed drug registry. The registry contains information on 
prescriptions on some regions in Sweden from June 2004, and has full, national 
coverage since 1 January 2006. Information on antidepressant use was also available 
from self-reported responses gathered in the SALT interview. Combining both data 
sources, a total of 6287 individuals had been prescribed antidepressants. 
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Additional information 
Self-reported weight and height was available from the interview and body mass index 
(BMI) was calculated for the purpose of being included as a covariate. Information on 
self-reported smoking status, educational level, diabetes and hypertension was also 
taken from the interview. Educational level was based on five categories (1= 0-6 
educational years, 2 = 6.5-9 educational years, 3 = 9.5-12 educational years, 4 = 12.5-15 
educational years, 5 ≥ 16 educational years).  
Data handling and generation of descriptive statistics were performed in SAS version 
9.3. Cox proportional hazards regression using robust sandwich estimators to correct 
for correlated data was carried out in STATA 12.1. Number of days since entry to the 
study was used as the underlying time scale. Depression and antidepressant use were 
modeled separately as exposure variables with CVD as the outcome, both of these 
variables were modeled as time varying covariates. Subsequently, statistical interaction 
between antidepressants and depression as well as depression and gender were 
analyzed. Separate survival analyses for CHD and ischemic stroke were also carried out. 
Further, we restricted the definition of depression to only include those who had 
received a depression diagnosis before 1996. Date of baseline was 1 January 2006. End 
of follow up was occurrence of first CVD event, death, or 31 December 2009, whichever 
occurred first, thus the maximum follow-up time was 4 years. 
Covariates included in the fully adjusted model were; birth year, gender, smoking status 
(ever or never smoker), educational level, hypertension (within the 5 past years), 
diabetes and BMI.  
Results 
Depression and use of antidepressants were both significantly associated with CVD 
outcome. There was however evidence for statistical interaction between depression 
and antidepressant use (HR=0.65, p=0.036) but not between depression and gender 
(HR=0.88, p=0. 51). After adjusting for all covariates the interaction term between 
depression and antidepressants was nearly significant (HR=0.69, p=0.069). Therefore 
we subdivided the exposure groups to “depression only” for depressed patients not 
using antidepressants, “depression and antidepressant users” for depressed patients on 
antidepressants and “antidepressants users only” for antidepressant users without a 
depression diagnosis.  
In the fully adjusted model, significant increased risk of CVD development was observed 
among the depressed only group as well as among the antidepressant only group. 
Among depressed patients who also used antidepressants, a modest and non-significant 
increased risk was observed (HR=1.21, p=0.12) (Table 6). Among those who have ever 
been depressed, the HR was estimated to be higher for those who have not used 
antidepressants compared to those who have used antidepressants.  
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Table 6 Hazard ratios for the association between clinical depression, antidepressant use 
and CVD  
*Adjusted for birth year and gender 
†Adjusted for birth year, gender, smoking status, educational level, hypertension, 
diabetes and BMI. 
The results from a proportional hazards model which fitted the associations between 
depression, antidepressants and CHD or ischemic stroke are depicted in Table 7. 
Depression was associated with a marked increase in risk of developing incident stroke 
regardless of exposure to antidepressant status, there was no significant association 
between ”antidepressants users only” and stroke. Neither depression nor 
antidepressant use were significantly associated with CHD (Table 7).  
  
Model 1* Model 2† 
Variable HR (95% 
CI) 
P-
value 
Variable HR (95% 
CI) 
P-
value 
Depression only 1.60 
(1.19, 
2.15) 
0.002 Depression only  1.50 
(1.11, 
2.02) 
0.008 
Antidepressants only  1.23 
(1.08, 
1.40) 
0.002 Antidepressants only 1.17 
(1.03, 
1.34) 
0.017 
Depression + 
Antidepressants 
1.28 (1.0, 
1.64) 
0.046 Depression + 
Antidepressants 
1.21 
(0.95, 
1.55) 
0.12 
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Table 7 Hazard ratios for the association between depression, antidepressant use and 
CHD or stroke. 
*Adjusted for birth year, gender, smoking status, educational level, hypertension, 
diabetes and BMI 
In order to limit the influence of reverse causality between depression and stroke we 
performed analyses in which we restricted the definition of depression to only include 
those who had received a depression diagnosis before 1996. (i.e. at least 10 years before 
baseline). In a fully adjusted model, the significant association between depression and 
stroke (HR=1.70, p<0.01) remained.  
Discussion 
This large prospective population-based study on elderly Swedish citizens shows that 
depression is an important risk factor for later development of CVD. The strongest 
association was observed for depression without use of antidepressants. This indicates 
that associations between antidepressants and CVD observed in in this study and 
previous studies could have been due to confounding by indication. Confounding by 
indication means that the indications for drug use (depression is an indication for use of 
antidepressants) could confound the drug-disease association so that it appears as if the 
drugs causes the disease 142.  Another important finding in this study is that the 
association with depression appeared to be specific to stroke and not CHD. We could 
also show that the association remained for stroke when only looking at depression 
diagnoses recorded before 1996.  
Depression has been more widely studied in relation to CHD rather than stroke 75,79 but 
we found depression to be more strongly associated with stroke. A recent 
comprehensive meta-analysis found the association between depression and future 
CHD Stroke 
Variable HR (95% 
CI)* 
P-
value 
Variable HR (95% 
CI)* 
P-
value 
Depression only 1.28 
(0.80, 
2.06) 
0.28 Depression only  1.78 
(1.16, 
2.74) 
0.009 
Antidepressants only 0.99 
(0.79, 
1.23) 
0.90 Antidepressants only 1.18 
(0.96, 
1.45) 
0.13 
Depression + 
Antidepressants 
0.81 
(0.52, 
1.27) 
0.36 Depression + 
Antidepressants 
1.74 
(1.26, 
2.40) 
0.001 
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stroke to be significant 76. However, two previous studies investigating depressive 
symptoms in relation to both CHD and stroke in the same study population had the 
opposite finding compared to ours 143,144. The reason may have been due to 
dissimilarities in study characteristics, definition of exposure and outcome as well as 
exclusion criteria. None of the two aforementioned studies used clinical records to 
define depression. In the Nabi et al. study 143, all participants who had had a CHD or 
stroke event at baseline (1998) were excluded. However it was not stated if those who 
had another type o CVD event prior to baseline also were excluded, thus reverse 
causality could have been an issue in their study design. Wassertheil-Smoller et al. 144, 
conducted separate analyses for those with a CVD history and those without, using self-
reported data for identifying prevalent cases. But the validity of self-reported CVD data 
might be questionable. 
This study does not recommend the use of antidepressants as a proxy measurement for 
depression. It is important to point out that antidepressants are not exclusively used to 
treat depression, other conditions for which antidepressants are used include anxiety 
disorders, obsessive compulsive disorders, eating disorders, chronic pain, 
posttraumatic stress disorder, and social phobia 145,146. 
We found a weaker association with CVD for depressed patients who did receive 
antidepressants compared to those we did not use antidepressants. Nevertheless, we 
cannot draw the conclusions that antidepressants indeed are CVD protective. It should 
be mentioned that the “depressed only” group in this study did not receive less medical 
drug prescriptions in general, they actually received more prescriptions for warfarin 
and antihypertensive drugs (beta blockers not included) compared to the other 
exposure groups (data not shown).  
Depression and use of antidepressants are variables that change over time, and in order 
to reduce misclassification bias during the follow-up period, we modeled the exposures 
as time varying covariates. However the change in exposure status was only modeled 
when an unexposed study subject turned into an exposed subject, if the order was the 
reverse it was not taken into account in the model. Some of the other covariates such as 
BMI can also vary over time but they could not be modeled as time varying covariates 
due to lack of longitudinal data.  
It is possible to adjust for “familial confounding” employing family-based designs, such 
as the co-twin control design. But, it would not be feasible to conduct such a method 
since both depression and antidepressants were modeled as time varying covariates. 
What more is, there would have been a significant loss o of power since only complete 
twin pairs could be included in such study designs. It is worth mentioning that the 
validity of the co-twin control design is based on several strong assumptions. For 
instance, measurement error of the exposure variable can easily distort the results, and 
there undoubtedly exists issues with misclassification of the exposure variables in our 
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cohort.  Methodological issues with family-based designs have been discussed 
thoroughly in a previous paper 147. 
It is important to point out that the study design does not permit inference on causality. 
We cannot conclude that clinical depression by itself causes CVD development. The 
observed association could for instance be the result of unmeasured confounders or 
residual confounding. Also, using self-reported data for diabetes, BMI, educational level 
and hypertension is far from optimal, actual measurements on blood pressure, height 
and weight would have been advantageous.  
A big study limitation is that information from primary care is lacking. A majority of 
those who develop depression after 65 years only come in contact with primary care 
and are not admitted to specialized psychiatric care in Sweden. Hence, they do not get 
their depression diagnosis reported in the national patient register 58. It is possible that 
the effects of depression on CVD and stroke risk were biased due to misclassification of 
exposure in those above 65 years of age.  
The study suggests that individuals who at some point in life are clinically depressed 
should be monitored more closely for their increased risk of developing CVD, 
particularly ischemic stroke. Further studies are needed to confirm and gain a deeper 
understanding of the association between clinical depression and stroke. 
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5.4 Study IV 
With the aim to bring further clarity to the relationship between depression and stroke, 
we here investigated if study participants with any record of clinical depression or self-
reported depressive symptoms had increased risk for incident stroke morbidity and 
mortality after adjusting for a range of stroke risk factors.  
Materials and methods 
The study material was obtained from the Twingene study 94 and the SALT interview. In 
total, 12,647 individuals participated by donating blood to the TwinGene study, by 
undergoing a health examination, and by answering a questionnaire about lifestyle and 
health between May 2004 and 2008. Sampling and clinical blood test procedures have 
been described elsewhere 96. Twingene has been linked to the Swedish national patient 
register, the causes of death register, and the Swedish psychiatric registry.  
Information on depression diagnoses and CVD diagnoses were obtained through linkage 
to the national patient register (inpatient and outpatient register) and the Swedish 
psychiatric registry. Detailed description on clinical depression and stroke definition 
has been reported elsewhere 148.  
Identification of Self-reported depression cases 
The 11-item CES-D was administered during the SALT interview, which is a modified 
shorter version of the original 20-item CES-D. Shorter versions of the 20-item CES-D 
have been recommended to be used to screen for current depression among elderly, 
since study participants of old age have been shown to experience difficulties 
completing the longer version 149.  The 11-item CES-D consists of 11 questions 
regarding feelings and symptoms of depressive mood over the past week. Each question 
is scored from 0-3, thus the maximum score possible is 33. The recommended cut-point 
of 9 was used to define depressive mood 150. 
Information on covariates  
Information on use of antihypertensive drugs, lipid lowering therapy, presence of 
diabetes, presence of migraine and birth weight was obtained from self-reported 
questionnaires from TwinGene. Study participants’ height and weight were measured at 
the local health care facility. Body mass index (BMI) was derived from these two 
variables. Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were 
assessed by using the average of two measurements after five minutes of rest. 
Information on participant’s low density lipoprotein (LDL), high density lipoprotein 
(HDL) and C-reactive protein (CRP) levels were taken from the TwinGene 
measurements. Information on smoking status and alcohol consumption (ever or never 
smoker/drinker) were taken from the SALT interview. Cases of atrial fibrillation were 
identified from the national patient register with the ICD codes: (ICD-10; I48), (ICD-9; 
427D), (ICD-8; 427.92), and (ICD-7; 433.12-3).  
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Statistical analyses 
Data handling and generation of descriptive statistics were performed in SAS version 
9.3. Cox proportional hazards regression using sandwich estimators to correct for 
correlated data was carried out in STATA 12.1. The TwinGene study was conducted 
between 2004 and 2008 and the date of baseline varied accordingly. Number of days 
since baseline (entry to the TwinGene study) was used as the underlying time scale. All 
study participants who had ever been diagnosed with clinical depression before 
censoring were classified as exposed to depression. Clinical depression and atrial 
fibrillation were modeled as time-varying covariates. End of follow-up was 31 
December 2010 rendering the maximum follow-up time to be 6.5 years. The primary 
outcome was stroke, including ischemic stroke, hemorrhagic stroke, and transient 
ischemic attack (TIA). Clinical depression and CES-D rated depression were modeled 
separately as exposure variables 
Covariates included in the fully adjusted model were; age, sex, atrial fibrillation, BMI, 
HDL, self-reported diabetes, SBP, DBP, self-reported use of antihypertensive medication, 
lipid lowering therapy, alcohol intake and smoking status. Values for BMI were missing 
for 529 study participants, for 659 study participants for DBP and 658 individuals had 
missing information on SBP. For subjects missing information on SBP, DBP or BMI 
imputed values were obtained by using the average SBP, DBP or BMI of their 
corresponding age group (in 5 year intervals). Associations between LDL and CRP levels 
with stroke were also assessed, however since none of these biomarkers were 
associated with stroke outcome and had many missing values they were omitted from 
the fully adjusted models. In addition, birth weight and migraine were also analyzed in 
relation to stroke, however they were not associated with the outcome and also omitted 
from the final statistical models. The proportional hazards assumption was examined 
with Schoenfeld’s residuals. If the assumption was violated by any of the covariates, that 
covariate was stratified in the proportional hazards model which enabled different 
baseline hazards for the different levels of the covariate.  
Results 
Descriptive characteristics by exposure and outcome group are depicted in Table 8. The 
proportion of stroke was higher among those who were clinically depressed compared 
to those who were not diagnosed with depression. Among those who had been 
diagnosed with depression only 29% had been classified as having CES-D depressive 
symptoms.  
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Table 8 Descriptive characteristics by exposure or outcome category 
Variable (unit) Non-depressed 
(SD) 
Clinically 
Depressed (SD) 
No stroke 
(SD) 
Stroke (SD) 
N 10941 397 10981 357 
Age at study 
entry (years) 
64 (7.9) 64 (7.7) 64 (7.9) 71 (7.7) 
Clinical 
Depression (%) 
 
- - 3.5 6.4 
CES-D score 
depression (%) 
8.9 
 
29.0 9.6 9.2 
Stroke/TIA (%) 3.1 5.6 - - 
*Values are means and standard deviations (SD) or percentages at baseline except for 
clinical depression where information was also collected during follow up period.  
Clinical depression was significantly associated with stroke, but CES-D rated depressive 
symptoms were not. The results from the crude model and the fully adjusted model for 
clinical depression and stroke were very similar, the hazard ratio (HR) was 2.24 in the 
crude model and 2.23 in the adjusted model (Table 9).  
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Table 9 Association between depression and stroke 
a adjusted for age and sex 
b adjusted for age, sex, BMI, SBP, DBP, HDL, diabetes, smoking, alcohol intake, 
antihypertensives, statins, and atrial fibrillation. 
c Stratified for antihypertensives 
 
Results from analyses specifically investigating the associations between clinical 
depression and ischemic stroke/TIA or hemorrhagic stroke are shown in Table 10. The 
results from the crude and fully adjusted models were very similar. The association was 
significant for ischemic stroke/TIA (HR=2.16, p=0.003) after adjusting for all covariates: 
The corresponding point estimate for hemorrhagic stroke was larger but non-significant 
(HR= 2.46, p=0.14).  
 
                     Model 1a Model 2b 
Variable No 
cases 
HR (95% CI) P-
value 
HR (95% CI) P-
value 
All stroke/TIA 357     
Diagnosed depression  2.24 (1.44, 
3.48)  
<0.001 2.23c (1.42, 
3.49) 
0.001 
CES-D score 
depression 
 1.19 (0.83, 
1.70) 
0.34 1.24c (0.86, 
1.79) 
0.25 
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Table 10 Association between depression and ischemic stroke/TIA or hemorrhagic stroke 
 
a adjusted for age and sex 
b adjusted for age, sex, BMI, SBP, DBP, HDL, diabetes, smoking, alcohol intake, 
antihypertensives, statins, and atrial fibrillation. 
c Stratified for dichotomized DBP 
Discussion 
In this study we could show that clinical depression is a prospective risk factor for 
stroke in individuals free of CVD at baseline even after adjusting for a battery of stroke 
risk factors. We could not find a significant association between self-reported 
depressive symptoms and stroke. Further, the association with clinical depression was 
similar in magnitude for stroke of both ischemic (including TIA) and hemorrhagic type, 
but only statistically significant for the former. Due to the smaller number of 
hemorrhagic stroke outcomes (N=44) it may just reflect lack of statistical power. It 
would be prudent to examine the relationship between depression and hemorrhagic 
stroke more rigorously in a study sample with a sufficient number of events.  
To our knowledge this is the first study which has compared how diagnosed 
depressions obtained from patient registers and self-reported depressive symptoms are 
related to incident stroke in the same material. It is worth mentioning that these are 
two very different measurements of depression. The clinical diagnoses consisted of any 
event of unipolar depression of varying severity that could be detected in the national 
patient register or psychiatric registry from 1960’s and onwards, the self-reported 
depressive symptoms were based on the 11-item CES-D administered during the SALT 
interview and examining depressive mood during the week before the interview. 
From the meta-analysis by Pan et al. it is possible to distinguish between studies which 
have used clinical diagnoses on depression examined by a physician/psychologist and 
                     Model 1a Model 2b 
Variable No 
cases 
HR (95% CI) P-
value 
HR (95% CI) P-
value 
Ischemic 
stroke/TIA 
300     
Diagnosed 
depression  
 2.15 (1.31, 
3.52) 
0.003 2.16 (1.30, 3.56) 0.003 
Hemorrhagic stroke 44     
Diagnosed 
depression 
 2.52 (0.78, 
8.15) 
0.12 2.46c (0.73, 
8.27) 
0.14 
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self-reported depression diagnoses. By combining the meta-analysis 76 with the results 
from study III and study IV it is possible to obtain pooled estimates of the RR for clinical 
diagnoses and self-reported diagnoses separately (excluding studies using mixed 
clinical/self-reported definition of depression diagnoses 151). Using a random effects 
model a pooled estimate of the relative risk (RR) found in studies that have used clinical 
diagnoses to define depression could be estimated to RR=2.49, CI 1.71-3.62 (test for 
heterogeneity, p <0.01). The corresponding pooled estimate for studies using self-
reported depressive symptoms was found to be RR=1.32, CI 1.21-1.45 (test for 
heterogeneity, p=0.03). This could be indicative of a dose-response relationship.  
We used a broad definition of unipolar depression, including dysthymia which is 
regarded as a milder chronic mood disorder separate from the cluster of major 
depressive disorder (MDD) subtypes 152. This was necessary since ICD-7 and ICD-8 
versions did not have different codes to distinguish between subtypes of clinical 
depression. A DSM-IV definition of MDD would have allowed for a more homogenous 
exposure variable. But a previous study which conducted separate analyses for MDD 
and dysthymia to investigate their associated risks with stroke outcome reported that 
the risk estimates were very similar153. In this study we attempted to compare CES-D 
self-reported measurement with clinical measurement of depression. It is thus 
important to note that the CES-D is used as a tool to measure “depressed mood” which 
is not specific to MDD. Moreover, subtypes of depression are defined according to the 
manifestation of symptoms, they are not based on distinct pathophysiological 
mechanisms 59. 
A majority of those who develop depression after 65 years of age are not admitted to 
specialized psychiatric care in Sweden and therefore do not get their depression 
diagnosis reported in the national patient register 58, and the psychiatric registry covers 
psychiatric admissions only before 1983. Therefore, the association between 
depression and stroke reported in this study could have been biased.  
We cannot conclude that the relationship between depression and stroke is causal, the 
observed association could for instance be due to unmeasured or residual confounding. 
Biological confounders/mediators suggested by earlier studies to contribute to the link 
between depression and stroke include increased platelet activation 80,154,155 which was 
unaccounted for in this study. There is also a possibility that depression might be a 
symptom of a prior silent brain infarction 156, and it has been reported that silent brain 
infarctions increases the risk for future stroke 157.  
In conclusion, evidence showing that clinical depression is a contributor to stroke 
development is increasing. Biological mechanisms underlying the observed association 
between depression and stroke have yet to be unraveled. Prospective studies 
elucidating the biological mechanisms behind the relationship between depression and 
stroke are required.   
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6 General discussion 
6.1 Methodological considerations 
“A hair, they say, divides the False and True…” 
Omar Khayyam (1048-1131), mathematician, astronomer, philosopher and poet. 
In this section some very general methodological issues in epidemiological studies are 
brought up. Accuracy in population studies relies upon random errors (precision) and 
systematic errors (biases). Only systematic errors (which affect the validity of the 
study) will be addressed herein. 
6.1.1 Internal validity (bias) 
Selection bias 
Selection biases arise due to factors influencing the selection of study subjects and study 
participation and lead to distortions of the study results 158. The obvious source of 
selection bias in the study material used in this PhD thesis is that only twins were 
included, non-twin population was excluded. In addition, only elderly individuals of 
Swedish origin were selected. TwinGene might particularly be subject to selection bias, 
both twins in a twin pair must have survived at least until May 2004, and in order to 
participate the twins had to be healthy enough to visit a local health facility and donate 
blood. In TwinGene the proportion of clinically depressed individuals was considerably 
low (2.9%), while it was 5.1 % in SALT. What more is, the proportion of smokers in 
Twingene is lower than that of the general Swedish population 159. It is possible that 
TwinGene might suffer from a “healthy volunteer effect”, and consequently the risk 
estimates could to some degree be biased 160. 
Selection bias and biased heritability 
It has been reported that selection bias can inflate additive genetic and unique 
environmental components and attenuate shared-environmental component.  High 
levels of selection bias could also result in spurious non-additive genetic components 
161. Heritability estimates will only be biased if the propensity to be included in a study 
is correlated with the phenotype of interest. When there is differential participation in 
relation to the phenotype of interest the estimate of the population correlation between 
twins will be reduced, and this effect will be larger for the lower correlation (the DZ 
correlation is often lower than the MZ correlation). As mentioned earlier, age had an 
effect on the tendency to participate with a peak in participation for subjects born 
between 1936 and 1940. The age window was even narrower in Study II 162, with mean 
age around 80 years old (standard deviation ~ 4 years), both Lp-PLA2 and anti-PC are 
correlated with age.  In addition, there were also other criteria for inclusion into the 
study which is listed in Study I 96. It can be debated whether excluding observations of 
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CRP values above 10 mg/L before conducting the heritability analyses on CRP ( higher 
CRP values reflect infection induced inflammation) was the best decision.   
Confounding (mixing of effects) 
 
Confounders are variables in a statistical model which are associated with both the 
exposure and outcome of interest, hence a spurious association between the exposure 
and outcome of interest might be observed solely due to the confounder if unaccounted 
for. Thus in statistical models assessing epidemiological relationships, variables 
suspected to be potential confounders need to be conditioned on 158. Confounders and 
biased associations have particularly been discussed in studies III and IV.  
 
Figure 3. Direct acyclic graph delineating the relationship between an exposure (E) a 
confounder (C) and an outcome (O) 
Colliders 
In some instances an exposure and outcome of interest might both contribute to a third 
variable, a collider. As a hypothetical example a disease might either be caused by risk 
factor E (exposure of interest) or risk factor O (outcome of interest). Say that there is no 
association between these two risk factors, but we attempt to investigate the causal 
relationship between risk factor E and risk factor O by conditioning on the disease (the 
collider), this can give rise to a spurious negative association between risk factor E and 
O. The collider could also be a register (if the exposure and outcome status affects the 
likelihood of being included in the register)  used as material for an observational study, 
in that case a selection bias (only selecting individuals included in the register) could 
introduce a spurious association between exposure and outcome  163. 
 
E OC
 
Figure 4. Direct acyclic graph illustrating the relationship between an exposure (E) a 
collider (C) and an outcome (E) 
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Mediators 
 
Mediators are variables in a statistical model which mediates the casual effect of the 
exposure on the outcome of interest. More specifically, the exposure variable causes a 
change in the level of the mediator variable which in turn affects the outcome variable. 
The mediator is said to be in the “causal pathway” between the exposure and outcome 
of interest. In studies III and IV it was difficult to distinguish between potential 
confounders and mediators. 
 
E OM
 
Figure 5. Direct acyclic graph illustrating the relationship between an exposure (E) a 
mediator (M) and an outcome (E) 
Dealing with mediators can be precarious since erroneously adjusting for a mediator 
can in fact give rise to a spurious association between the exposure and outcome. Such 
biased associations can occur when the association between the mediator and the 
outcome variable is confounded, in a direct acyclic graph these confounders would be 
termed as ancestors to colliders.  
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Figure 6. Direct acyclic graph delineating the relationship between an exposure (E) a 
perceived mediator (M) ancestor to a collider (C) and an outcome (O) 
 
 
Reverse causality 
Reverse causality denotes the chicken and the egg dilemma, i.e. what is perceived as the 
order of exposure-outcome relation in a study setting is actually reversed in reality. 
When the exposure variable is time varying and the outcome variable is hard to 
measure, or when molecular processes are cyclic (reciprocal causality), reverse 
causality can beset epidemiological studies. In study III, we attempted to reduce the 
potential for reverse causality, by restricting the exposure variable (depression 
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diagnosis) to be registered at least 10 years before the outcome (incident CVD 
diagnosis). However, reverse causality can also be a problem even when temporality, i.e. 
the exposure is measured at a time point preceding the measurement of the outcome, is 
included in the study design. The exposure and outcome variables in the study are 
usually proxy measurements of the true exposure and outcome, and it is not feasible to 
have access to data on the time varying exposure measured at every single time point 
throughout a study subject’s life, the same applies for the outcome variable.  Reverse 
causality also applies to mediators and confounders, in study IV it was difficult to 
determine whether blood pressure was a confounder or mediator in the association 
between depression and stroke. Depression diagnoses were usually reported before 
baseline while blood pressure measurements were taken at baseline, intuitively blood 
pressure could be perceived as a mediator. However, some depression diagnoses were 
reported at a time point after baseline. The association was only significant when 
assessing blood pressure and depression where blood pressure measurement was 
preceding the depression diagnoses, the association was not significant when the blood 
pressure measurement succeeded the depression diagnoses (Supplementary table S3).  
Given those results, it becomes evident that blood pressure could possibly have exerted 
a confounding effect. Owing to reverse causality it can be very difficult to discern 
between confounders, mediators and colliders.  
Information bias (Misclassification bias)  
In this section varieties of misclassification bias (measurement error of discrete 
variables) most likely to have been affecting the studies belonging to this thesis will be 
discussed. Misclassification bias simply refers to measurement errors of the exposure 
variable, the outcome variable or any of the other covariates included in a model of 
interest. Non-differential misclassification of exposure refers to the situation when 
there is a misclassification of the exposure variable which is not dependent on the other 
variables in the model. Non-differential exposure misclassification is regarded to 
weaken the association between exposure and outcome, i.e. lead to an underestimation 
of the true effect, although this notion has been challenged by simulation studies since it 
does not consider other conditions such as random error 164. Non-differential 
misclassification of a dichotomous confounding variable will not fully adjust for that 
particular confounder and thus the association between the exposure and outcome will 
remain biased. 
Differential misclassification bias on the other hand arises when misclassification of 
exposure is dependent of other variables in the model. Differential misclassification of 
exposure can either lead to either an underestimation or overestimation of the true 
effect.  Studies III and IV were afflicted by differential misclassification of clinical 
depression depending on age, study participants above 65 years of age were more likely 
to be misclassified as non-depressed.  Age is positively associated with stroke outcome, 
if assuming that the pathophysiology of early-onset and late-onset depression do not 
45 
 
differ the misclassification of depression is likely to have resulted in an underestimation 
of the depression-stroke association.  
6.1.2 External validity 
Generalizability 
The population used in an epidemiological study is a sample from a target population 
158. Generalizability refers to how representative the study population is of the target 
population. There are concerns regarding the generalizability of the study population 
utilized in the constituent studies of my thesis. Our study population consists of Swedish 
twins and twins might differ from singletons regarding levels of risk factors and disease. 
What more is, we might not be able to extrapolate our findings to other ethnicities. 
According to a former study based on STR there was no difference in CVD risk and death 
when comparing twins with singletons 165. In the fourth study the incidence rate for 
ischemic stroke was 6.8 per 1000 person-years (average age 70 years old). This is 
slightly higher than has been previously reported by a study on stroke incidence on 
cohorts based on Finnish and Swedish populations aged 60-69 years 166.  Moreover, an 
earlier study based on STR reported that the incidence rates of psychiatric illness were 
similar between twins and singletons 167.  
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7 Concluding remarks 
Study I 
The study emphasizes the importance of acknowledging the contribution of non-
additive genetic effects to the risk of CVD. The results imply that dominant genetic 
models also should be considered when molecular studies are conducted in order to 
identify genes associated or linked to CVD blood biomarkers analyzed in the study. 
Moreover, unique environmental factors were shown to significantly impact all of the 
studied traits. The study also suggests that the equal environment assumption should 
be examined when conducting heritability studies on twin populations. 
 
Study II 
The study confirms that Lp-PLA2 has a heritable component, although the 
environmental component contributing to trait variance was larger than what has 
previously been reported. It was also the first study to conduct variance partitioning on 
anti-PC levels, revealing both a genetic and unique environmental component 
underlying trait variance. Given that both of these biomarkers have previously been 
suggested to be associated with CVD risk and that anti-PC appears to be independent 
from other risk markers, further examination of Lp-PLA2 and anti-PC’s role as CVD 
biomarkers is necessitated. Genetic variants found to be associated with Lp-PLA2 
include genetic variants related to LDL, apoB, and TC levels, therefore the genetic 
correlation estimated in multivariate twin analyses could indicate genetic pleiotropy. 
Study III 
This large prospective population-based study indicates that depression is an important 
risk factor for later development of CVD. The association with depression was more 
pronounced for ischemic stroke risk, while neither antidepressants nor depression 
were associated with CHD. Nevertheless, since many previous studies have found a 
positive association between depression and CHD75 replication of these non-significant 
findings in other studies is warranted. The association with CVD was strongest among 
depressed patients who have not used antidepressants. But the study design does not 
permit any conclusions on biological interactions, since for example the patients that 
did not consume antidepressants could have been affected by an additional set of risk 
factors than those who did use antidepressants.  We also conclude that in general, use of 
antidepressants should not be utilized as a proxy measurement for depression. The 
study suggests that individuals who at some point in life are clinically depressed should 
be monitored more closely for their increased risk of developing CVD, particularly 
ischemic stroke. Further studies are needed to confirm and gain a deeper understanding 
of the association between clinical depression and stroke. 
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Study IV 
In conclusion, evidence showing that clinical depression is a contributor to stroke 
development is increasing. The association was not accounted for by any of the 
covariates used in this study, including several important stroke risk factors. Studies 
conducting rigorous analyses on the link between depression and different stroke 
subtypes would be very valuable. Biological mechanisms underlying the observed 
association between depression and stroke have yet to be unraveled. We observed a 
marked difference in strength of association for self-reported depression compared to 
clinical depression. This indicates that extra caution is warranted when using self-
reported index of depressive symptoms in epidemiological settings as a proxy for 
clinical depression. Prospective studies elucidating the biological mechanisms behind 
the relationship between depression and stroke are required, for not only would they 
enhance our biological understanding of stroke, but also provide clues about the 
mechanisms behind depression. 
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8 Future perspectives 
8.1 Studies I and II 
The last years, genome-wide data have revolutionized the ability to detect genetic risk 
variants underlying a range of biological traits. Nevertheless, in many cases these risk 
variants only explain a small proportion of the proposed heritability of the traits 168. In 
this section novel ways on how to identify genetic risk variants underlying biological 
traits as well as how to estimate heritability will be discussed. In a paper by Yang et al. it 
was shown that common genetic variants do explain around half of the heritability for 
human height 169,170. They showed this by applying a linear model to regress phenotypic 
similarity on genotypic similarity utilizing SNP data on a population consisting of 
unrelated individuals. Instead of inferring about additive relatedness from pedigree 
information (as is done in twin studies) this information is taken from SNP data, since 
the population consists of unrelated individuals the problem with shared environment 
was solved. They found that additive genetic effects explained 45% of the variance in 
height, which is much less than what has been found using classical twin design (80%), 
but much larger than had been discovered in genome-wide association studies (10%). 
The authors reasoned that the missing heritability of 35% was due to incomplete 
linkage disequilibrium (LD) between the SNPs in the chip and many of the actual causal 
genetic variants, and that individually these causal variants have small effects. In other 
words, genetic variants who are not in LD with SNPs in common chip arrays (rare 
genetic variants or variants in genomic regions poorly covered by the chip SNPs) with 
small effect sizes would explain the remaining heritability, however since they used an 
identity-by-state approach 171 on population with small sample size it was difficult to 
capture the contribution of many of the causal genetic variants. The authors concluded 
that prospective genome-wide studies of very large sample sizes will be required to 
detect genetic variants with very low minor allele frequency and small effect sizes. 
A study by Zuk et al. provided a different explanation for the missing heritability, they 
concluded that the missing heritability is not missing at all, rather that genetic 
interactions (epistasis) create phantom heritability 172. Their biological reasoning was 
that in many instances several biological inputs (e.g. proteins or chemical reactants) are 
required for a biological process to take place. They also referred to several studies on 
model organisms in which epistasis have been found 173,174. They introduced a thinking 
framework on how this could be affecting heritability estimates by developing a limiting 
pathway (LP) model. Briefly, the LP model assumes that many biological traits depends 
on a number of rate-limiting inputs (k), these inputs themselves follow a standard 
additive model (the variance is explained by additive genetics and environmental 
factors).  If k=1 then the LP model is additive, however if k is greater than 1 then 
according to the LP model this will result in phantom heritability, in other words the 
phantom heritability will increase as the number of k increases. The authors 
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rationalized that complex biological traits will more likely be affected by epistasis and 
consequently phantom heritability than traits of simpler biological architecture.  
They proposed a model for heritability estimation based on unrelated individuals in 
recent genetically isolated population, isolated populations because then an identity-by-
descent (IBD) 171 approach can be used. Hence, it would be more possible to capture the 
causal genetic variants with lower minor allele frequency. Simply put, with dense 
genotype data it could be possible to measure if the phenotypic similarity between 
individuals depends on genetic similarity (IBD sharing). They do not recommend 
methods based on relatives since they share alleles to a very large degree making it very 
difficult to tease apart epistasis from additive genetic effects. Moreover the levels of 
shared environment might vary between different constellations of relatives which 
further complicate the estimation of heritability. This model bears resemblance with the 
model utilized by Yang et al. 170, with the major difference being that it should be 
conducted on genetically isolated populations.  
It remains to see if many more genetic variants will be found as study sample sizes 
increase and if indeed the genetic variance explained by genotypes will greatly increase. 
Or if the heritability (more specifically the additive heritability) measured by classical 
family design is inflated due to genetic interactions. Either way, developments of novel 
methods for estimating heritability, especially in an era where we have access to 
extensive molecular genetic data, should be promoted.  
8.2 Studies III and IV  
Many improvements can be made in observational studies investigating the association 
between depression and CVD. The construction of a clinical depression variable is least 
to say challenging. Many factors need to be considered, heterogeneity has been a major 
methodological limitation in studies III and IV, the specificity of the diagnoses was 
however weighed against sensitivity. The use of ICD-7 and ICD-8 codes brings with it a 
great deal of uncertainty of depression classification, a range of psychiatric conditions 
could particularly be included in ICD-7 where only one code is available for defining 
depressive mood. A possible solution would be to use a cohort consisting of a younger 
population and only confining to diagnostic codes from ICD-9 and ICD-10. Collection of 
medical records in which DSM-IV classifications are included would of course facilitate 
in obtaining a more detailed and accurate definition of depression.  
To my knowledge, validation studies on unipolar depression diagnoses in the Swedish 
national patient register has yet to be performed. A study validating unipolar 
depression in the Danish Psychiatric Central Research Register found the validity to be 
satisfactory, around 75% of the patients who had received a single depressive episode 
in the register could also be diagnosed with single depressive episode according to 
Schedules for Clinical Assessment in Neuropsychiatry interview 175. Extrapolating their 
results might be adequate due to ethnic/cultural similarities. Moreover, the psychiatric 
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care in Denmark and Sweden are to a large extent non-privatized, and the use of ICD-10 
codes has been in practice since 1990’s in both countries. Nonetheless, it would be 
prudent to carry out a study to assess the validity of unipolar depression diagnoses in 
the Swedish national patient register, and extend it to comprise diagnoses such as 
recurrent depressive disorder.   
In future study designs it could be interesting to model the degree of depression 
severity, in order to capture a plausible dose-response relationship between depression 
and CVD. A former study demonstrated that the way ICD-10 grades unipolar depressive 
disorder (mild, moderate, severe) is clinically useful, since it predicts relapse and 
suicidal risk 176.  Variables such as admissions to inpatient versus outpatient hospital 
settings, the number of hospital admissions due to depression, and the age of 
depression onset could also be included in the models since they are indicative of 
depression severity.  Inspection of comorbid conditions, by for instance thoroughly 
scanning through the additional ICD-coded diagnoses at each hospital admission could 
result in the finding of a major confounder. But considerations of these variables would 
require huge sample sizes and a real effort to reduce selection bias. 
In study III, when investigating the relationship between antidepressants, depression 
and CVD, the strongest association with CVD was observed for depressed patients who 
did not use antidepressants 177. This might have implied that associations between 
antidepressants and CVD observed in study III as well as previous studies could have 
been due to confounding by indication. The exact relationship between antidepressants 
and CVD is however debatable due to the very conflicting results presented in previous 
studies. One recent large population-based study suggested that depressed patients that 
used antidepressants with higher affinity for the serotonin transporter have a slightly 
elevated risk of stroke compared to users of antidepressants with lower affinity for the 
serotonin transporter 178. This would be interesting to study more thoroughly in other 
study populations. A review by the Cochrane stroke review group based on 56 trials 
investigating the effect of SSRI on stroke recovery found that overall SSRIs appeared to 
improve disability, neurological impairment, and depression after stroke. They could 
not find any evidence that one type of SSRI was superior to another. They advised that 
efforts should be made on conducting prospective large-scale trials to assess whether 
SSRI indeed is beneficial for stroke recovery and should be given routinely to stroke 
patients 179. 
Finally, access to high quality data for CVD ascertainment and health status such as 
neuroimaging data (CT and MRI scans), electrocardiography measurements, data from 
coronary/neurovascular angiography, duplex imaging of extracranial arteries, and 
measurements of physical activity would provide a higher accuracy of outcome and 
covariate definitions. It could however be fair to assume that severely depressed 
patients are less prone to take part in cohorts where a very active participation is 
necessary, thus register-based data might sometimes offer the best solution.   
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11 Supplementary Tables 
Table S1 Age at use of antidepressant and stroke risk 
Exposure group N antidepressant 
users 
Hazard ratio ( 95% 
CI ) 
P-
value 
Antidepressants (≤50 years) 607 2.12 (1.30-3.46) 0.003 
Antidepressants (>50 years) 5636 1.15 (1.01-1.30) 0.035 
Adjusted for birth year, sex, educational level, smoking status, hypertension and BMI. If 
the first record of antidepressant use was found in the SALT interview, then age at SALT 
interview was used. 
Table S2 Age at depression diagnosis and stroke risk 
Exposure group N depressed Hazard ratio ( 95% CI ) P-value 
Clinical depression (≤50 years) 835 1.83 (1.21-2.76) 0.004 
Clinical depression (>50 years) 1032 1.62 (1.17-2.26) 0.004 
Adjusted for birth year, sex, educational level, smoking status, hypertension and BMI 
Table S3 Association between SBP and depression adjusted for age and sex 
 
 Model 1  Model 2 
No cases OR (95% CI) P-value No cases 
 
OR (95% CI) P-value 
311 0.99 (0.99-1.00) 0.11 85 0.99 (0.97-0.99) 0.02 
Model 1: Depression preceding SBP measurement (unit mmHg) 
Model 2: SBP measurement (unit mmHG) preceding depression diagnosis 
 
 
 
